CCR5 and coronary artery disorder: Ultimately, since CCR5 not only controls effector T cells but also directs Tregs and moves them into inflamed non-lymphoid tissue, assuming that CCR5+ Tregs constitute a subgroup of ‘effector’ Tregs cells, the levels of circulating CCR5+ Tregs were evaluated in both subclinical carotid artery patients and patients with CAD.